Invivo Anti-Mouse IFN-β Recombinant mAb

IFN-β, or interferon-beta, is a pleiotropic cytokine belonging to the type I interferon family, encoded by the IFNB1 gene on human chromosome 9 and primarily induced by various cells—such as fibroblasts and plasmacytoid dendritic cells—upon viral or bacterial infection. Its core function serves as the first line of innate immunity: upon binding to its cell-surface heterodimeric receptor (composed of IFNAR1 and IFNAR2 subunits), IFN-β activates the JAK-STAT signaling pathway, which in turn induces the expression of hundreds of interferon-stimulated genes (ISGs). The proteins encoded by these genes exert broad-spectrum antiviral effects (e.g., blocking viral replication, degrading viral RNA), inhibit cell proliferation, and modulate immune responses. Beyond its critical role in antiviral infection, IFN-β also possesses important immunomodulatory functions—it promotes the maturation and activation of dendritic cells and T cells, enhances natural killer cell cytotoxicity, while simultaneously restraining excessive inflammatory responses through mechanisms such as regulating Treg cells, thereby exerting a bidirectional regulatory role in immune homeostasis. Based on these properties, recombinant human IFN-β has been widely applied in clinical practice, with its most notable indication being multiple sclerosis, where it delays disease progression through anti-inflammatory and neuroprotective effects. Additionally, IFN-β has been explored in the treatment of certain solid tumors, such as melanoma. However, its clinical use is constrained by significant side effects (e.g., flu-like symptoms, myelosuppression) and potential resistance mechanisms within the tumor microenvironment, prompting ongoing research into combination therapies and novel delivery strategies to optimize its therapeutic efficacy.